• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 108

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

The Psychedelic News Feed: January 12 – 18, 2026

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and Open Questions

Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

Numinus Wellness Inc. Executives to Present on Panel at Upcoming South...

Reunion Neuroscience to Participate in the Oppenheimer Annual Healthcare Conference

Small Pharma Announces Further Positive Data from SPL026 Phase IIa Trial...

atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates

Mindset Pharma and PharmAla Complete First Sale of Pharmaceutical Grade Psilocybin...

Psychedelic Bulletin #132: COMPASS Pathways Amends Phase 3 Program; Stamets Stack...

Webinar – Unraveling the Top 3 Psychedelic Neuroscience Myths

Webinar – A Somatic Perspective on Sex & Psychedelics: Focusing on...

Psychedelics Weekly – Cannadelic, Concussions, Vital, and More PT News

How To Get Your Start as a Psychedelic Informed Practitioner

1...107108109...306Page 108 of 306

EDITOR PICKS

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

The Psychedelic News Feed: January 12 – 18, 2026

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©